Reported 4 months ago
The article discusses how Pfizer's stock, previously boosted by successful COVID-19 products, might face challenges as demand declines. The company aims to diversify its portfolio and generate new revenue streams, but short-term challenges include patent expirations and cost-cutting measures. Despite a potential long-term turnaround plan, investors might need to brace for a bumpy ride as Pfizer navigates through these transitions.
Source: YAHOO